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Abstract Once the sequence of a genome is in hand, under-
standing the function of its encoded proteins becomes a task of
paramount importance. Much like the biochemists who first
outlined different biochemical pathways, many genomic scientists
are engaged in determining which proteins interact with which
proteins, thereby establishing a protein interaction network.
While these interactions have evolved in regard to their
specificity, affinity and cellular function over billions of years,
it is possible in the laboratory to isolate peptides from
combinatorial libraries that bind to the same proteins with
similar specificity, affinity and primary structures, which
resemble those of the natural interacting proteins. We have
termed this phenomenon ‘convergent evolution’. In this review,
we highlight various examples of convergent evolution that have
been uncovered in experiments dissecting protein^protein inter-
actions with combinatorial peptides. Thus, a fruitful approach for
mapping protein^protein interactions is to isolate peptide ligands
to a target protein and identify candidate interacting proteins in a
sequenced genome by computer analysis. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Natural evolution, as de¢ned by Charles Darwin, consists
of three essential phases (Fig. 1). First, a population of or-
ganisms is placed in an environment that selects for some
individuals over others. Second, those individuals that are
favored pass on their ‘winning alleles’ to progeny. Third, con-
tinued rounds of diversi¢cation and selection lead to opti-
mized phenotypes and genotypes. Many aspects of this pro-
cess can be found in experiments in molecular evolution (Fig.
1), in which a diverse population of molecules is generated
through combinatorial chemistry, the molecules are then sub-
jected to a selection step, and, if they are based on a biological
expression system, additional rounds of selection are applied.
Thus, from a library of millions to billions of di¡erent mole-
cules generated in a combinatorial fashion, it now is possible
to isolate optimized ligands to many protein targets.
One major di¡erence between natural and molecular evolu-
tion is that typically the selected molecules are not permitted
to undergo additional diversi¢cation through mutation or re-
combination. However, it is possible to take a sequence se-
lected from a combinatorial library and then to generate a
second combinatorial library that is varied around the selected
sequence. These ‘biased’ or ‘directed’ libraries often yield even
stronger binding entities [1,2]. Alternatively, it is possible to
propagate selected phage in an error-prone bacterial strain [3]
or to shu¥e the insert DNA following each round of selection
[4,5].
As will be discussed below, screening combinatorial peptide
libraries by a⁄nity selection often yields peptide ligands that
resemble the primary structures within interacting proteins
(Fig. 2). This seems to occur especially often when the inter-
action between two proteins involves a short contiguous
stretch of peptide residues in one interacting protein and a
peptide-binding pocket in the other protein. In this review,
we highlight various examples where the peptides selected
for binding to a protein resemble a region within a known
or putative interacting protein(s). Thus, mapping protein^pro-
tein interactions with combinatorial peptides can be just as
fruitful an approach in proteomics research as yeast two-hy-
brid screening of cDNAs [6].
2. De¢ning the speci¢city of protein interaction modules
A large number of protein^protein interactions in eukary-
otic cells have been shown to involve protein interaction mod-
ules and their cognate ligands. These modules include the Src
homology 2 (SH2), Src homology 3 (SH3), phosphotyrosine-
binding, WW, Eps15 homology (EH), PSD-95/dlg/ZO1 (PDZ)
and Ena/VASP homology domains, to name a few. The struc-
ture and function of these domains have been the subject of
recent reviews elsewhere [7^11]. In general, the modules bind
short continuous regions within interacting proteins. To de¢ne
the speci¢city of these protein interaction modules, combina-
torial peptide libraries have been used to isolate peptide li-
gands, and very often there is an excellent correspondence
between the primary structures of the peptide ligands and
regions within known interacting proteins.
2.1. SH3 domains
SH3 domains typically bind proline-rich peptides with the
motif PxxP, where x may be any amino acid [12]. Phage-dis-
played and chemically synthesized combinatorial peptide li-
braries have been used to de¢ne the speci¢city of individual
SH3 domains. In this manner, the speci¢city of SH3 domains
of Abl [13], amphiphysin I [14], cortactin [13], Fyn, Grb2 [13],
Lyn [15], phosphatidylinositol 3-kinase [16] and Yes [13] has
been determined.
For example, the optimal ligand consensus de¢ned for one
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of the two SH3 domains in Crk is PxLPxK, where x is any
amino acid. As seen in Fig. 3A, this ligand sequence is present
in Abl (PLLPTK), C3G (PALPPK), cDNA clone ST12
(PGLPSK), DOCK 180 (PPLPLK) and Eps15 (PALPPK),
which were originally identi¢ed as Crk-interacting proteins
by ‘traditional means’ (i.e. immunoprecipitation, far Western
blotting, screening cDNA expression libraries) [17^20]. Thus,
if the sequence of the entire mouse genome was known, scan-
ning the mouse proteome for proteins bearing the PxLPxK
motif could have identi¢ed the same ¢ve proteins as candidate
Crk-interacting proteins.
The three-dimensional structure of the N-terminal SH3 do-
main of Crk complexed with a peptide segment of C3G has
been solved [21]. In the structure (Fig. 3B), the central six
residues (PALPPK) of the peptide adopt a left-handed poly-
proline type II helix that ¢ts into the three shallow hydro-
phobic pockets of the SH3 domain. Interestingly, the four
residues within the peptide that make contact with the surface
of the SH3 domain (Fig. 3B) are the same ones conserved
among the phage-displayed peptide ligands (PxLPxK).
2.2. WW domains
This domain was originally characterized as a short, 35
amino acid repeat found in human, mouse and chicken ho-
mologues of the Yes-associated protein (YAP). The speci¢city
of the domain was ¢rst revealed when two proteins (WBP1
and 2) were identi¢ed by yeast two-hybrid analysis to bind to
the YAP WW domain [22]. Alanine scanning experiments of a
motif shared by both proteins, PPPPY, demonstrated that the
PPxY sequence is the site of binding for the WW domain.
WW domains have been used to select peptides from com-
binatorial phage-displayed libraries and these analyses sup-
port previous ¢ndings that certain WW domains bind a
PPxY motif [23]. Based on these phage-display-derived WW
domain ligands, predictions have been made regarding the
cellular ligands of the WW domain-containing proteins.
When the C-terminal WW domain of the mouse Nedd-4 pro-
tein, an ubiquitin ligase, is used to a⁄nity select peptides from
a phage-display combinatorial peptide library, peptides con-
taining the PPxY motif are isolated (Fig. 4). If the longer
consensus sequence (i.e. PPxYES(L/M)) is used to search
the Swiss-Prot protein database, one of the most interesting
matches is the L-subunit of human, rat, rabbit and frog epi-
thelial sodium channels (ENaC). This interaction is function-
ally signi¢cant, as truncations or substitutions within the
PPxY motif [24^26] give rise to Liddle’s syndrome, a form
of hypertension that is caused by extending the half-life of
the mutant ENaC subunits, which fail to be ubiquitinated
and subsequently degraded by the ubiquitin/26S proteosome
pathway [27].
2.3. EH domains
The EH domain mediates a number of important protein^
protein interactions in endocytosis and molecular tra⁄cking
[11]. EH domains are about 100 amino acids in length, and
bind short peptides in a hydrophobic pocket formed between
two K-helices [28,29]. When a phage-displayed library of com-
binatorial peptides was screened with the EH domains of
Eps15 [30] and intersectin [31], peptides containing the tripep-
tide motif, NPF, were isolated (Fig. 5). In support of this
result, cDNA segments encoding several novel proteins with
multiple NPF motifs [30,31] were isolated from a lambda-
cDNA expression library, when the same EH domains were
used as probes. The proteins have since been demonstrated to
be cellular ligands for Eps15 and intersectin [32^36] and likely
interact in a multivalent fashion [11,37]. Thus, analysis of the
Fig. 1. Comparison of biological and molecular evolution. On the
left, the steps of evolution are outlined as de¢ned by Charles Dar-
win. Populations of organisms, which are selected based on the
some trait, give rise to individuals who pass the selected alleles onto
the next generation. This process is repeated each generation, even-
tually leading to the production of highly optimized genes, proteins
and organisms. On the right, the steps of molecular evolution are
shown for comparison. Populations of molecules, which have been
generated by combinatorial chemistry, are selected by a⁄nity selec-
tion. If the molecules are linked to a biological system, the selected
molecules are propagated, ultimately yielding molecules that bind to
the target.
Fig. 2. Convergent evolution. In nature, two proteins evolve a
highly speci¢c interaction by adopting either a receptor or ligand
mode of interaction (left). Conversely, a receptor can select peptides
from phage-displayed combinatorial peptide libraries that represent
optimal ligands for the receptor (right). When the peptides selected
from the combinatorial libraries have the same primary structure as
the site within the natural cellular ligand, we have termed this ‘con-
vergent evolution’.
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molecular recognition properties of EH domains provides an
excellent example of convergent evolution between combina-
torial peptides and natural proteins.
2.4. PDZ domains
Another well-studied protein interaction module is the PDZ
domain. PDZ domains were ¢rst described as 80^100 amino
acid repeats within the post-synaptic density 95 protein [38],
and since then, 685 examples have been identi¢ed in over 370
eukaryotic proteins [39]. In their ‘classical’ mode of recogni-
tion, PDZ domains bind to peptide sequences at the C-termini
of certain membrane proteins, where the free carboxylate
group docks into a highly conserved hydrophobic pocket on
the PDZ domain surface and the side chains ¢t within a pep-
tide-binding groove of the domain [40,41]. Speci¢city in bind-
ing is de¢ned by the 3^8 amino acid residues preceding the C-
terminus [41^43]. Ligand preferences for various PDZ do-
mains have been de¢ned with chemically synthesized combi-
natorial peptide libraries immobilized on cellulose membranes
[44,45] or in solution [43].
Another example of the remarkable convergent evolution
seen with combinatorial peptides was the independent predic-
tion that the syntrophin PDZ domain can interact with volt-
age-gated sodium channels (VGSCs) [44]. The optimal ligand
preference for the K-syntrophin PDZ domain was de¢ned by
screening a library of combinatorial peptides immobilized on
membranes to be (K/R)E(S/T)xV-COOH. Interestingly, the
sequence (K/R)ES(L/I)V-COOH is present at the C-terminus
of the K-subunits of all known vertebrate VGSCs [44]. This
match was biologically signi¢cant, since it has been independ-
ently shown that the VGSCs of skeletal and cardiac muscles
copurify with syntrophin from extracts of skeletal and cardiac
Fig. 3. Isolation of peptides and proteins that bind to the N-terminal SH3 domain of the oncoprotein Crk. Crk is a protein believed to act at
the interface of the cytoskeleton and signal transduction, and contains two SH3 domains and a single SH2 domain. A: A phage-display combi-
natorial (x6PxxPx6) peptide library was screened for peptide ligands to the N-terminal SH3 domain of Crk and the consensus sequence is
shown [13], where x is any amino acid. Also listed is the motif within C3G, DOCK 180, Eps15 and clone ST12 [19,20] identi¢ed to bind to the
N-terminal SH3 domain of Crk. B: The three-dimensional structure of the N-terminal SH3 domain of Crk has been solved while complexed
with a peptide segment, PPPALPPKKR, of C3G [21]. The surface of the SH3 domain is shown with blue and red denoting positive and nega-
tive electrostatic charges, respectively, along with the central six residues (PALPPK) of the C3G peptide. The PDB coordinates (1CKA) of the
complex were modeled with the program WebLab ViewerLite (version 3.2) from Molecular Simulations Incorporated (http://www.msi.com).
Fig. 4. Isolation of peptides and proteins that bind to the central WW domain of mouse Nedd-4. Nedd-4 is a signal transduction protein,
which contains a C2 domain, three WW domains and an ubiquitin ligase catalytic domain [92]. A phage-display combinatorial (X12) peptide li-
brary was screened for peptide ligands to the C-terminal WW domain of Nedd-4 and isolated ligands are shown on the left. The N-terminal
peptide ligand for the domain contains the core motif, (L/P)PSY. Computer searches with this motif (boxed) identi¢ed the ENaC of Xenopus
laevis as a potential interacting protein.
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muscles [46]. In addition, this interaction can be competed
with peptides corresponding to the C-terminal 10 amino acids
of the cardiac and skeletal muscle VGSC K-subunits, indicat-
ing that the syntrophin PDZ domain interacts with the chan-
nels through their C-terminal peptide sequences.
Songyang et al. [43] used a panel of nine di¡erent PDZ
domains to fractionate chemically synthesized random peptide
libraries in solution. The optimal peptide ligands predicted by
the selected peptides were in good agreement with sequences
present at the C-termini of known interacting proteins of the
PDZ domains tested.
The requirement for a free carboxylate group has limited
the use of phage-displayed libraries in de¢ning the speci¢city
of PDZ domains, since peptides are typically displayed at the
N-terminus of proteins III or VIII of bacteriophage M13.
However, it was possible to select peptide ligands from a
Fig. 5. Isolation of peptides and proteins that bind to the EH domains of intersectin. Intersectin is a protein component of the endocytic ma-
chinery, and contains two EH domains, a central region believed to adopt a coiled-coil structure, and ¢ve SH3 domains [11]. A phage-display
combinatorial (X9) peptide library was screened for peptide ligands to the N-terminal EH domain of intersectin; the isolated ligands are shown
on the left [31]. The optimal peptide ligand for the domain contains the core motif, NPF. A mouse cDNA expression library [31], which was
screened with the same EH domain, yielded three di¡erent sequences: Rev-associated binding proteins RAB [90], also known as the Rev-inter-
acting protein (Rip) [91] or Hrb [34], and epsin-1 [32] and epsin-2. In the C-terminal region of the three proteins are 3^4 copies of the NPF
motif (underlined).
Table 1
List of recent experiments with combinatorial peptides exhibiting convergent evolution
Protein Peptide ligand motif Matching sequence Putative interacting protein References
Cortactin SH3 domain +PP8PxK KPPVPPK CortBP1, Shank [13,93,94]
Amphiphysin I SH3 domain PxRPx(R/H)(R/H), #xRPxP PSRPNR, PIRPSR Dynamin, Synaptojanin [14,95]
Endophilin 1 SH3 domain 8+RPPPP PKRPPPP Synaptojanin [95]
Eps8 SH3 domain PxxDY PxxDY E3b1/Abi-1 [96]
EH domains of Eps15 and intersectin NPF NPF Epsins, Numb, Rev/Rip [30,31]
YAP WW domain PPxY PPPY YAP [22,23]
Grb2 SH2 domain PPYxN8 pYVNV SHC [97]
Cbl SH2 domain D(N/D)xpY SDGpY ZAP-70 [98]
PDZ domain (K/R)E(S/T)C(L/M) (K/R)ES(L/I)V VGSCs [44,99]
Estrogen receptor K LxxLL LxxLL Transcriptional activators [55,100]
DM2 FxDxWxxL FSDLWKLL p53 [89,101]
Caveolin xxxxxxxx WSYGVTVW Tyrosine kinases [102,103]
HIV-1 Vpr WxxF WEQF Uracil DNA glycosylase [104]
Troponin C (V/L)(D/E)xLKxxLxxLA LKTLLLQIA Troponin I [105]
Vinculin DVYDWARRVS DVYTKKELIECARRVS Talin [106]
PP1c Vx(F/W) Vx(F/W) Many PP1 regulatory proteins [59]
Integrins:
KvL1 RGD RGD Fibronectin [107,108]
KvL3 RGD RGD Fibronectin [109]
KvL3 SFFARR SLFAFR Vitronectin [110]
KvL6 DLxxL DLxxL Extracellular matrix components [111]
8 represents hydrophobic residues (i.e. I, L, P, V), x represents aromatic residues (i.e. W, F, Y), + represents positively charged residues (i.e.
K, R), and x represents any residue. pY refers to a phosphorylated tyrosine residue.
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library of cysteine-cyclized combinatorial peptides at the
N-terminus of protein III with the PDZ domain of K-syntro-
phin. The consensus of the selected peptides, (K/R)ETC(L/
M), was very similar to the peptide sequence, V(K/R)ES(L/
I)V-COOH, which is present at the C-termini of the K-sub-
units of VGSCs [44].
The isolation of a cyclized peptide ligand for the PDZ do-
main of K-syntrophin suggested that this domain can recog-
nize non-C-terminal peptide sequences. Recently, the three-
dimensional structure of a heterodimer between the PDZ do-
mains of K-syntrophin and neuronal nitric oxide synthase has
con¢rmed this suggestion, by demonstrating that the PDZ
domain of K-syntrophin interacts with internal peptide se-
quences present within a speci¢c secondary structure [47].
2.5. Various protein targets
Over the last few years, a number of examples supporting
the concept of convergent evolution have been published. Ta-
ble 1 lists those instances where the peptide ligands to various
proteins that have been isolated from combinatorial peptide
libraries resemble or match peptide sequences present within
interacting proteins. The text below focuses on selected entries
in Table 1.
The half-life of the tumor suppressor protein p53 is regu-
lated in part by its binding to the ubiquitin ligase, DM2
[48,49]. When the N-terminal 140 amino acids of DM2 were
used to screen phage-displayed combinatorial peptide libraries
[50], the selected peptides share the consensus xFxDxWxxLx,
which is strikingly similar to a sequence at the N-terminus of
p53, TFSDLWKLLP (amino acids 18^27). Interestingly, the
same residues that are conserved also ¢t within the hydro-
phobic pocket of DM2 [51].
The conformational state of the estrogen receptor (ERK) is
di¡erentially a¡ected by the binding of its ligands, such as
estradiol and anti-estrogen drug tamoxifen [52,53]. Depending
on the ligand bound, the receptor is hypothesized to expose
di¡erent surfaces, thus engaging di¡erent or overlapping sets
of protein components of the transcriptional machinery. Re-
cently, phage-displayed combinatorial peptide libraries have
been used to probe estradiol^ERK and tamoxifen^ERK com-
plexes [54,55]. Intriguingly, several of the peptides isolated
that bound to the estradiol-activated ERK contained the se-
quence LxxLL, a ‘signature motif’ of nuclear receptor co-ac-
tivators [55]. On the other hand, screens with the tamoxifen-
activated ERK yielded a very di¡erent set of peptides, with the
consensus (S/M)RE(W/F)FxxxL. Searches of databases with
this consensus revealed similar sequences in the yeast protein
RSP5 and its human homologue, receptor potentiating factor
1. Although the biological signi¢cance of these matches re-
mains to be clari¢ed, both proteins are known to act as co-
activators of progesterone and glucocorticoid receptors in
mammalian and yeast cells [56].
Combinatorial peptides displayed on the surface of bacteria
have been used to ¢nd peptide ligands to proteins. The entire
coding sequence of Escherichia coli thioredoxin (trxA) was
inserted into a dispensable region of the gene for £agellin
(£iC), the major structural component of the E. coli £agellum,
and the resulting recombinant protein (FLITRX) has been
used to display combinatorial peptides on the surface of bac-
teria [57,58]. Not only has this system been used to de¢ne the
epitopes of various monoclonal antibodies [57], but it has
been used to isolate peptide ligands to the catalytic subunit
of protein phosphatase 1 (PP1c) [59]. The PP1c-binding pep-
tides share the motif Vx(F/W), where x is often H or R; in
addition, the motif is commonly preceded by 2^5 basic resi-
dues and followed by one acidic residue. Interestingly, this
motif occurs in a number of PP1c regulatory proteins [60]
and structural studies have shown that it ¢ts within a hydro-
phobic channel present in the C-terminal region of PP1c [61].
Yeast two-hybrid screening of combinatorial peptides has
also been used to identify peptide ligands to a variety of
protein targets. The retinoblastoma protein (Rb) has been
used as ‘bait’, fused to the Gal4 DNA-binding domain, to
search for interacting combinatorial peptides, fused to a tran-
scriptional activation domain [62]. Out of an initial pool of
three million transformants, seven peptides that bound Rb
were discovered. Interestingly, these peptides shared the motif
LxCxE, which is present in natural proteins such as adenovi-
rus protein E1A, transcription factor E2F and cyclin D that
have been previously shown to interact with Rb.
The heterodimerization domain of the E2F1 transcription
factor has been used as bait to screen a library of 20-mer
combinatorial peptides constrained within a loop of the E.
coli thioredoxin protein [63]. One of the peptides isolated,
RCVRCRFVVWIGLRVRCLV, contained a sequence similar
to the KEKKEIWIGL in the heterodimerization domain of
DP1, a physiological binding partner of E2F1. The biological
signi¢cance of this match was supported with the observations
that mutagenesis of the WIGL peptide sequence in DP1 mark-
edly reduced its ability to heterodimerize with E2F1, and that
introduction of the peptide into cells inhibited both the for-
mation of functional E2F1/DP1 heterodimers and E2F1-regu-
lated gene expression. These results suggest that the peptides
selected from the combinatorial peptide library approximate
the manner in which DP1 binds to E2F1.
However, not all peptides isolated from yeast two-hybrid
screening contain sequences that match known interacting
proteins. When peptides that bind to cyclin-dependent kinase
2 (Cdk2) were isolated from a library displayed in the E. coli
thioredoxin protein [64], they failed to match any known pro-
tein, even though the peptides could inhibit interaction of
Cdk2 with one of its substrates [65]. Speci¢c inhibitors of
this type represent a powerful tool for studying genetic net-
works inside cells. Recently, peptides were selected that block
cell-cycle arrest in MATa Saccharomyces cerevisiae cells that
have been exposed to K-factor [66]. From a collection of 38
peptides isolated in an initial selection experiment, a subset of
12 peptides was used as bait in two-hybrid screens of cDNAs.
This screening revealed a gene previously not believed to be
involved in pheromone response, Cbk1 (cell wall biosynthesis
kinase 1), along with protein components of other cell-cycle
pathways in yeast. Peptides that speci¢cally block the spindle
checkpoint, inhibit transcriptional silencing or block phero-
mone signaling have also been identi¢ed in an analogous man-
ner, although they have not been extensively characterized
[67].
Combinatorial peptide libraries displayed on phage have
been isolated using selectively infective phage. In this novel
method, combinatorial peptides are fused to the C-terminal
domain of a soluble form of protein III, whereas the protein
target is fused to the N-terminal domain of protein III at-
tached to phage particles [68,69]. When there is an intermo-
lecular interaction between the two ‘halves’ of the protein III
molecule, infectivity is restored to the phage particles. This
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technique has been used to select disul¢de-constrained pep-
tides that bind to the death domain of the p75 neurotrophin
receptor [70]. Twenty-eight peptides that bound this target
were recovered and sequenced, however database analysis
failed to identify any sequence similarity between the recov-
ered peptides and known proteins.
Finally, it should be mentioned that it is possible to isolate
peptides that bind to non-proteinaceous targets [71]. For ex-
ample, peptides have been isolated from combinatorial libra-
ries that bind to biotin [72], plastic [73], single-stranded (ss)
DNA [74], £uorescent dyes [75], taxol [76] or polyglutamine
tracts within proteins involved in neurodegenerative diseases
[77]. While many of these peptides do not resemble known
interacting proteins, the motif shared by the ss DNA-binding
peptides is present in the E. coli ss DNA-binding protein [74]
and the taxol-binding peptides were used to predict success-
fully that Bcl-2 does interact with taxol inside cells [76].
3. Why do combinatorial peptide libraries often yield
biologically relevant peptide ligands?
Data from mutagenesis studies of various protein^protein
interfaces suggest that the binding energy is not evenly dis-
tributed over the protein interaction surfaces, but rather con-
centrated in energetic ‘hot spots’, in which only a small subset
of the residues accounts for most of the change in free energy
[78]. Elegant studies on the interaction between human growth
hormone (HGH) and its receptor have revealed that of 30 or
so residues comprising the interaction interface, only a small
hydrophobic region of the receptor, dominated by two tryp-
tophans, accounts for more than three quarters of the binding
free energy. Similarly, only eight residues of HGH (217 amino
acids) account for 85% of the binding energy [79,80]. In a
study characterizing the epitopes of several monoclonal anti-
bodies to HGH [81,82], it was discovered that typically less
than three residues critically de¢ne each epitope. In another
study, scanning mutagenesis of the interaction interface be-
tween the Shaker potassium channel and the 37 amino acid
long charybdotoxin of scorpions revealed that only two resi-
dues contributed most of the binding, even though 15 residues
of the toxin are involved in the interaction [83^85].
The highly uneven distribution of the binding energy
throughout a protein^protein interface may help to explain
why peptides selected from a combinatorial library by a target
protein are so similar to the sequences of the physiologically
relevant interacting proteins. The consensus residues in the
selected peptides are the residues that are critical for binding,
like the ‘teeth’ of the ‘key’ in the commonly used ‘lock and
key’ metaphor. This is especially true for linear, unconstrained
random peptides, where amino acid positions are relatively
independent in their contribution to binding [86].
Examples of convergent evolution occurring at protein^pro-
tein interaction surfaces can be found in nature as well. Re-
cently, the three-dimensional structure of the bacterial in-
tegrin-binding protein, invasin, has been solved [87].
Remarkably, the integrin-binding surfaces of invasin and ¢-
bronectin present the same key residues, two aspartic acids
and an arginine, in the same relative spatial locations, but
in the context of di¡erent folds and surface shapes. Thus,
convergent evolution can occur in nature between di¡erent
host and bacterial proteins.
4. Perspectives
The concept of convergent evolution has important impli-
cations in the analysis of the proteome in sequenced genomes.
The genome of the yeast, S. cerevisiae, has been sequenced
and the primary structures of its protein products have been
cataloged in computer databases. The yeast genome contains
12 million bp and encodes 6027 potential proteins, for a total
of 2.8 million amino acids [88]. Given that there are 3.2 mil-
lion (205) mathematically possible di¡erent 5-mer peptide se-
quences, in a genome the size of yeast most 5-mer sequences
are expected to occur approximately once in the genome, as-
suming randomness. Though the coding capacity of the ge-
nome is likely not random, due to functional and structural
needs, once the ligand preferences for a protein interaction
module or a target protein have been de¢ned to ¢ve residues,
a manageable number (i.e. 6 5) of putative interacting candi-
dates will result from database ‘mining’. These candidates can
then be tested for their ability to interact with the module or
target protein by a variety of methods (i.e. co-immunopreci-
pitation, cross-linking, yeast two-hybrid screening, etc.).
In this review, we have highlighted several recent examples
of convergent evolution of protein^protein interactions
achieved with combinatorial peptides. While not all peptide
ligands selected for binding to a target match the primary
structure of the interacting protein, a surprising number do.
Thus, a fruitful means of mapping protein^protein interac-
tions is to isolate peptide ligands to a target protein and
identify candidate interacting proteins in a sequenced genome
by computer analysis. The identi¢cation of protein interaction
networks should accelerate functional analysis of proteomes
and drug discovery [89].
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